Publikationsserver der Universitätsbibliothek Marburg
Titel:Evaluierung der Krankheitsaktivität von Pemphigus-Patienten mittles des Autoimmune Bullous Skin Disorder Intensity Scores.
Autor:Müllers, Anne
Weitere Beteiligte: Hertl, Michael (Prof.Dr.)
Veröffentlicht:2010
URI:https://archiv.ub.uni-marburg.de/diss/z2010/0202
DOI: https://doi.org/10.17192/z2010.0202
URN: urn:nbn:de:hebis:04-z2010-02024
DDC: Medizin
Titel (trans.):Evaluation of disease activity in pemphigus patients by the autoimmune bullous skin disorder intensity score (ABSIS)
Publikationsdatum:2010-03-09
Lizenz:https://rightsstatements.org/vocab/InC-NC/1.0/

Dokument

Schlagwörter:
Score, ABSIS, Pemphigus, ABSIS, Score, Pemphigus, ABSIS, pemphigus, scroing system

Zusammenfassung:
Bisher gibt es keinen einheitlichen Bewertungsmaßstab zur Beurteilung der Krankheitsaktivität von Pemphigus-Patienten. Für diese Studie wurde ein neues Score-System entwickelt, der Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), und an Pemphigus-Patienten prospektiv untersucht.

Bibliographie / References

  1. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol 122, 409-415.
  2. Torzecka, J.D., Wosniak, K., Kowalewski, C.,Waszczykowska, E., Sysa- Jedrzejowska, A., Pas, H.H., Narbutt, J. (2007). Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? Arch Dermatol Res 299:239– 243.
  3. Eming, R., Rech, J., Barth, S., Kalden, J.R., Schuler, G., Harrer, T., Hertl, M. (2006). Prolonged Clinical Remission of Patients with Severe Pemphigus upon Rapid Removal of Desmoglein-Reactive Autoantibodies by Immunoadsorption. Dermatology 212:177–187.
  4. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110, 103-109.
  5. Ding, X., Aoki, V., Mascaro, J.M., Lopez-Swiderski, A., Diaz, L.A., Fairley, J.A. (1997). Mucosal and Mucocutaneous (Generalized) Pemphigus Vulgaris Show Distinct Autoantibody Profiles. J Invest Dermatol 109:592-596.
  6. Pemphigus IgG, but not bullous pemphigoid IgG, causes a transient increase in intracellular calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 104, 33-37.
  7. Müller, R., Svoboda, V., Wenzel, E., Müller, H.-H., Hertl, M. (2008). IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Experimental Dermatology 17: 35–43.
  8. Tsunoda, K., Ota, T., Aoki, M., Yamada, T., Nagai, T., Nakagawa, T., Koyasu, S., Nishikawa, T., Amagai, M. (2003). Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 170, 2170-2178.
  9. Veldman, C.M., Gebhard, K.L., Uter, W., Wassmuth, R., Grotzinger, J., Schultz, E., und Hertl, M. (2004a). T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol 172, 3883-3892.
  10. Yeh, S.W., Cavacini, L.A., Bhol, K.C., Lin, M.S., Kumar, M., Duval, M., Posner, M.R., Ahmed, A.R. (2006). Pathogenic human monoclonal antibody against desmoglein 3. Clinical Immunology 120:68-75.
  11. Hashimoto, T., Amagai, M., Watanabe, K., Dmochowski, M., Chidgey, M.A., Yue, K.K., Garrod, D.R., Nishikawa, T. (1995). A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins.
  12. Moraes, M.E., Fernandez-Vina, M., Lazaro, A., Diaz, L.A. Filho, G.H., Friedman, H., Rivitti, E., Aoki, V., Stastny, P., Moraes, J.R. (1997). An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue Antigens. 49:35–40.
  13. Dakkak, M., Bennett, J.R. (1992). A new dysphagia score with objective validation. J Clin Gastroenterol 14(2): 99-100.
  14. Saraswat, A., Kumar, B. (2003). A new grading system for oral pemphigus. Int J Dermatol 42: 413-4.
  15. Kwon, E.J., Yamagami, J., Nishikawa, T., Amagai, M. (2008). Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. JEADV, 22, 1070– 1075.
  16. Joly, P., Mouquet, H., Roujeau, J.-C., D´Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.-L., Bedane, C., Muller, R., Dreno, B., Doutre, M.-S., Delaporte, E., Pauwels, C., Franck, N., Caux, F., Picard, C., Tancrede-Bohin, E., Bernard, P., Tron, F., Hertl, M., Musette, P. (2007). A Single Cycle of Rituximab for the Treatment of Severe Pemphigus. N Engl J Med 357:545-52.
  17. Tiling-Grosse, S., Rees, I. (1993). Assessment of area of involvement in skin disease: a study using schematic figure outlines. British Journal of Dermatology 128, 69 – 74.
  18. Eming, R., Hertl, M. (2006). Autoimmune bullous disorders. Clin Chem Lab Med 44(2):144–149.
  19. Hertl, M., Riechers, R. (2001). Autoreactive T Cells as Potential Targets for Immunotherapy of Autoimmune Bullous Skin Diseases. Clinics in Dermatology 19:592–597.
  20. Kunte, C., Barbosa, J.M., Wolff, H., Meurer, M. (1997). Brasilianischer Pemphigus foliaceus (Fogo selvagem). Hautarzt 48:228–233.
  21. Roscoe, J.T., Diaz, L.A., Sampaio, S.A., Castro, R.M., Labib, R.S., Takahashi, Y., Patel, H., Anhalt, G.J. (1985). Brazilian pemphigus foliaceus auto-antibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 85: 538– 541.
  22. Sitaru, C., Goebeler, M., Zillikens, D. (2004). Bullöse Autoimmundermatosen (I): Pathogenese und Diagnostik. JDDG 2: 123-139.
  23. Rose, E., Kasperkiewicz, M., Rose, C., Zillikens, D. (2007). Bullöse Autoimmundermatosen, Neues zur Diagnostik und Therapie. Der Deutsche Dermatologe 9: 617-62.
  24. Hertl, M., Schuler, G. (2002a). Bullöse Autoimmundermatosen Teil 1: Klassifikation. Hautarzt 53:207-221.
  25. Hertl, M., Schuler, G. (2002b). Bullöse Autoimmundermatosen Teil 2: Pathogenese. Hautarzt 53:277-285.
  26. Hertl, M., Schuler, G. (2002c). Bullöse Autoimmundermatosen Teil 3: Diagnostik und Therapie. Hautarzt 53:352-366.
  27. Can pemphigus vulgaris become pemphigus foliaceus? J Am Acad Dermatol 1991;25:797-800.
  28. Ishii, K., Amagai, M., Hall, R.P., Hashimoto, T., Takayanagi, A., Gamou, S., Shimizu, N., Nishikawa, T. (1997) Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159: 2010-7.
  29. Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab. Dermatology 218:237–245.
  30. Sams, W.M., Jordon, R.E. (1971). Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br J Der 84, 7-13.
  31. Rassner, G. (2007). Dermatologie Lehrbuch und Atlas. 8.Auflage. Elsevier Urban und Fischer, München.
  32. Lin, M.S., Swartz, S.J., Lopez, A., Ding, X., Fernandez-Vina, M.A., Stastny, P., Fairley, J.A., und Diaz, L.A. (1997b). Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 99, 31-40.
  33. Ishii, K., Amagai, M., Ohata, Y., Shimizu, H., Hashimoto, T., Ohya, K., Nishikawa, T. (2000). Development of pemphigus vulgaris in a patient with pemphigus foliaceus: Antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 42:859-61.
  34. Jainta, S., Schmidt, E., Bröcker, E.B., Zillikens, D. (2001). Diagnostik und Therapie bullöser Autoimmunerkrankungen der Haut. Dt Ärztebl 98: A 1320– 1325 [Heft 20].
  35. Veldman, C., Stauber, A., Wassmuth, R., Uter, W., Schuler, G., Hertl, M. (2003). Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV- Associated HLA Class II Alleles. J Immunol 170: 635–642.
  36. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 167, 5439-5448.
  37. Einsatz hochdosierter intravenöser Immunglobuline in der Dermatologie. JDDG 1:183-190.
  38. Diaz, L.A., Sampaio, S.A., Rivitti, E.A., Martins, C.R., Cunha, P.R., Lombardi, C., Almeida, F.A., Martins Castro, R., Macca, M.L., Lavrado, C., Filho, G.H., Borges, P., Minelli, L., Empinotti, J.C., Friedman, H., Campbell, J.I., Labib, R.S., Anhalt, G.J. (1989). Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol 20:657-69.
  39. Vanderlugt, C.J., Stephen, D, Miller, S.D. (1996). Epitope spreading. Current Opinion in Immunology 8:831-836.
  40. HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of Brazil. Immunogenetics 33: 388-391.
  41. Hertl, M. (2000). Humoral and Cellular Autoimmunity in Autoimmune Bullous Skin Disorders. Int Arch Allergy Immunol 122:91-100.
  42. Eyre, R.W. und Stanley, J.R. (1988).Identification of Pemphigus Vulgaris Antigen Extracted from Normal Human Epidermis and Comparison with Pemphigus Foliaceus Antigen. The Journal of Clinical Investigation 81, 807- 812.
  43. Müller, R., Svoboda,V., Wenzel, E., Gebert, S., Hunzelmann, N., Müller, H.-H., Hertl, M. (2006). IgG reactivity against non-conformational NH2-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris. Experimental Dermatology 15: 606–614.
  44. Vollmar, A., Dingermann, T. (2005). Immunologie Grundlagen und Wirkstoffe.
  45. Shimanovich, I., Herzog, S., Schmidt, E., Opitz, A., Klinker, E., Bröcker, E.-B., Goebeler, M., Zillikens, D. (2006). Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clinical and Experimental Dermatology, 31, 768–774.
  46. Pfütze, M., Niedermeier, A., Hertl, M., Eming, R. (2007). Introducing a new Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 17 (1): 4-11.
  47. Feliciani, C., Toto, P., Amerio, P., Pour, S. M., Coscione, G., Shivji, G., Wang, B., und Sauder, D.N. (2000). In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin- 1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114, 71-77.
  48. In Vitro Keratinocyte Dissociation Assay for Evaluation of the Pathogenicity of Anti-Desmoglein 3 IgG Autoantibodies in Pemphigus Vulgaris. J Invest Dermatol 124:939–946.
  49. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J. Invest. Dermatol. 110:76–78.
  50. Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression. British Journal of Dermatology 141: 1084- 1087.
  51. Welsch, U. (2006). Lehrbuch Histologie. 2. Auflage. Elsevier Urban und Fischer, München.
  52. Charman, C.R., Venn, A.J., Williams, H.C. (1999). Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 140: 109-11.
  53. Hertl, M., Karr, R.W., Amagai, M., und Katz, S.I. (1998b). MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 110, 388-392.
  54. Cheng, S.W., Kobayashi, M., Kinoshita-Kuroda, K., Tanikawa, A., Amagai, M., Nishikawa, T. (2002). Monitoring disease activity in pemphigus with enzyme- linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 147: 261-5.
  55. Merlob, P., Metzker, A., Hazaz, B., Rogovin, H., Reisner, S.H. (1986). Neonatal Pemphigus Vulgaris. Pediatrics 78;1102-1105.
  56. Campo-Voegeli, A., Muñiz, Mascaró, J.M., Casals, M., García, F., Arimany, J.L., Amagai, M., Camps, A. (2002). Neonatal pemphigus vulgaris with extensive mucocutaneous lesions from a mother with oral pemphigus vulgaris. British Journal of Dermatology 147: 801–805.
  57. Nguyen, V.T., Ndoye, A., Grando, S.A. (2000b). Novel Human a9 Acetylcholine Receptor Regulating Keratinocyte Adhesion is Targeted by Pemphigus Vulgaris Autoimmunity. Am J Pathol 157:1377–1391.
  58. Charman, C., Williams, H. (2000). Outcome Measures of Disease Severity in Atopic Eczema. Arch Dermatol. 136:763-769.
  59. Herbst, A., Bystryn, J.C. (2000). Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 42: 422-7.
  60. Emery, D.J., Diaz, L.A., Fairley, J.A., Lopez, A., Taylor, A.F., Giudice, G.J. (1995). Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol 104, 323-328.
  61. Morini, J.P., Jomaa, B., Gorgi, Y., Saguem, M.H., Nourira, R. Roujeau, J.C., Revuz, J. (1993). Pemphigus foliaceus in young women. An endemic focus in the Sousse area of Tunisia. Arch Dermatol 129: 69-73.
  62. Hertl, M., Veldman, C. (2001). Pemphigus – Paradigm of Autoantibody- Mediated Autoimmunity. Skin Pharmacol Appl Skin Physiol 14:408–418.
  63. Nguyen, V.T., Ndoye, A., Grando, S.A. (2000a). Pemphigus Vulgaris Antibody Identifies Pemphaxin A novel keratinocyte Annexin-like molecule binding acetylcholine. J Biol Chem 275: 29466–29476.
  64. Pemphigus Vulgaris Autoantibody Response is Linked to HLA-DQB1*0503 in Pakistani Patients. Human Immunology 57, 110–119.
  65. Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG- induced Inositol 1,4,5-Trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol 105, 329-333.
  66. Huber, O.(2003). Review Structure and function of desmosomal proteins and their role in development and disease. CMLS, Cell. Mol. Life Sci. 60 1872– 1890.
  67. Eming, R., Nagel, A., Wolff-Franke, S., Podstawa, Eva, Debus, D., Hertl, M. (2008). Rituximab Exerts a Dual Effect in Pemphigus Vulgaris. Journal of Investigative Dermatology 128, 2850–2858.
  68. Rituximab in refractory autoimmune bullous diseases. Clinical and Experimental Dermatology, 31, 503–508.
  69. Nagel, A., Podstawa, E., Eickmann, M, Müller, H.-H., Hertl, M., Eming, R. (2009). Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus Vulgaris. J Invest Dermatol 129 (9): 2202-10.
  70. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines Pediatr Allergy Immunol 8: 28-34.
  71. Fredriksson, T., Pettersson, U. (1978). Severe psoriasis -oral therapy with a new retinoid. Dermatologica 157: 238-244.
  72. Ahmed, A.R., Strominger, J.L. (1995). Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 92, 11935- 11939.
  73. Lombardi, C., Borges, P.C., Chaul, A., Sampaio, S.A.P.,Rivitti, E.A., Friedman, H., Martins, C.R., Sanches, J.A., Cunha, P.R., Hoffmann, R.G., Diaz, L.A., " The Cooperative Group on Fogo Selvagem Research " (1992). Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Invest Dermatol 98: 847–850.
  74. Schmidt, E., Klinker, E., Opitz, A., Herzog, S., Sitaru, C., Goebeler, M., Mansouri Taleghoni, B., Bröcker, E.-B., Zillikens, D. (2003).Therapeutics Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus British Journal of Dermatology 148: 1222–1229.
  75. Lin, M.S., Swartz, S.J., Lopez, A., Ding, X., Fairley, J.A., Diaz, L.A. (1997a). T- Lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1. J Invest dermatol 109:734-737.
  76. Mahajan, V.K., Sharma, N.L., Sharma, R.C., Garg, G. (2005). Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
  77. Kljuic, A., Bazzi, H., Sundberg, J. P., Martinez-Mir, A., O'Shaughnessy, R., Mahoney, M.G., Levy, M., Montagutelli, X., Ahmad, W., Aita, V.M., Gordon, D., Uitto, J., Whiting, D., Ott, J., Fischer, S., Gilliam, T.C., Jahoda, C.A.B., Morris, R.J., Panteleyev, Nguyen, V.T., Christiano, A.M. (2003). Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 113, 249-260.
  78. Jolles, S. (2001). A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clinical and Experimental Dermatology 26: 127-131.
  79. Hofmann, S.C., Kautz, O., Hertl, M., Sticherling, M., Zillikens, D., Bruckner- Tuderman, L. (2009). Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. JDDG 7:227– 233.
  80. Spaeth, S., Riechers, R., Borradori, L., Zillikens, D., Büdinger, L., Hertl, M. (2001). IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. British Journal of Dermatology 144: 1183-1188.
  81. Hertl, M., Amagai, M., Sundaram, H., Stanley, J., Ishii, K., und Katz, S.I. (1998a). Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 110, 62-66.
  82. Hertl, M., Eming, R., Veldman, C. (2006). T cell control in autoimmune bullous skin disorders. J. Clin. Invest. 116:1159–1166.
  83. Murrell, D.F., Dick, S., Ahmed, A.R., Amagai, M., Barnadas, M.A., Borradori, L., Bystryn, J.C., Cianchini, G., Diaz, L., Fivenson, D., Hall, R., Harman, K.E., Hashimoto, T., Hertl, M., Hunzelmann, N., Iranzo, P., Joly, P., Jonkman, M.F., Kitajima, Y., Korman, N.J., Martin, L.K., Mimouni, D., Pandya, A.G., Payne, A.S., Rubenstein, D., Shimizu, H., Sinha, A.A., Sirois, D., Zillikens, D., Werth, V.P. (2008). Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043-6.
  84. Rosenbach, M., Murrell, D.F., Bystryn, J.-C., Dulay, S., Dick, S., Fakharzadeh, S., Hall, R., Korman, N.J., Lin, J., Okawa, J., Pandya, A.G., Payne, A.S., Rose, M., Rubenstein, D., Woodley, D., Vittorio, C., Werth, B.B., Erik A. Williams, E.A., Taylor, L., Troxel, A.B., Werth, V.P. (2009). Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. J Invest Dermatol 129 (10):2404- 10.
  85. Mahoney, M.G., Wang, Z., Rothenberger, K., Koch, P.J., Amagai, M., Stanley, J.R. (1999). Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 103:461-468.
  86. Junqueira, L.C.U., Carneiro, J. und Gratzl M. (Hrsg.) (2005). Histologie.
  87. Role of intramolecular epitope spreading in pemphigus vulgaris. Clinical Immunology 116: 54 – 64.
  88. Kumar, B., Arora, S., Kumaran, M., Jain, R., Dogra, S. (2006). Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus. Indian Journal of Dermatology, Venereology and Leprology Vol.72, No 3: 203-206.
  89. Harman, K.E., Albert, S., Black, M.M. (2003). Guidelines for the management of pemphigus vulgaris. British Journal of Dermatology 149: 926–937.
  90. Harman, K.E., Seed, P.T., Gratian, M.J., Bhogal, B.S., Challacombe, S.J., Black, M.M. (2001). The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 144: 775-80.
  91. Harman, K.E., Gratian, M.J., Shirlaw, P.J., Bhogal, B.S., Challacombe, S.J. (2002). The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris. British Journal of Dermatology 146: 684–687.

* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten
© UB Marburg 1997 - 2024 Universitätsbibliothek Marburg